Keryx concludes patient recruitment in cancer drug Phase 3 trial
The Phase 3 trial which aims at over all survival, is a double-blind, randomized trial involved around 430 patients to compare the safety and efficacy of perifosine +
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.